ICON Public Limited Company logo

ICON Public Limited Company

ICLR

NASDAQHealthcareMedical - Diagnostics & Research

Previous close

$172.23

−$2.035 · -1.17%

Aug 21, 4:00 PM ET

ICLR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

79

Undervalued

Momentum

51

Neutral

Sentiment

54

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
IE
CEO
Barry Balfe
Listed since
May 15, 1998
Employees
40,200

Market position

Day range

Current $172.23

52-week range

Current $172.23

Open
$176.11
Previous close
$174.27
Volume
391.18K
0.37× average
Average volume
1.06M
Average daily volume
Market cap
13.19B USD
Beta
1.2
Market reference 1
50-day average
$164.27
+4.85% above average
200-day average
$147.14
+17.05% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
17.2B USD
EV / EBITDA
20.88×
Earnings yield
1.60%
Free cash flow yield
6.03%

Profitability & efficiency

Return on equity
2.49%
Return on assets
1.41%
Return on invested capital
6.74%

Financial health

Current ratio
1.1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends32%22%11%0%Gross margin, FY2021: 27.52%Gross margin, FY2022: 28.60%Gross margin, FY2023: 29.56%Gross margin, FY2024: 29.42%Gross margin, FY2025: 26.37%Operating margin, FY2021: 6.91%Operating margin, FY2022: 10.27%Operating margin, FY2023: 11.78%Operating margin, FY2024: 13.26%Operating margin, FY2025: 12.27%Net margin, FY2021: 2.79%Net margin, FY2022: 6.53%Net margin, FY2023: 7.54%Net margin, FY2024: 9.56%Net margin, FY2025: 2.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 27.52%. Gross margin FY2022 28.60%. Gross margin FY2023 29.56%. Gross margin FY2024 29.42%. Gross margin FY2025 26.37%. Operating margin FY2021 6.91%. Operating margin FY2022 10.27%. Operating margin FY2023 11.78%. Operating margin FY2024 13.26%. Operating margin FY2025 12.27%. Net margin FY2021 2.79%. Net margin FY2022 6.53%. Net margin FY2023 7.54%. Net margin FY2024 9.56%. Net margin FY2025 2.78%.

Income trends

Revenue

8.25B USD-0.37%

Operating income

1.01B USD-7.77%

Net income

229.34M USD-71.02%
Income trends across reported periods9.09B USD5.84B USD2.59B USD−659.66M USDRevenue, FY2021: 5.48B USDRevenue, FY2022: 7.74B USDRevenue, FY2023: 8.12B USDRevenue, FY2024: 8.28B USDRevenue, FY2025: 8.25B USDOperating income, FY2021: 378.53M USDOperating income, FY2022: 795.24M USDOperating income, FY2023: 956.15M USDOperating income, FY2024: 1.1B USDOperating income, FY2025: 1.01B USDNet income, FY2021: 153.19M USDNet income, FY2022: 505.3M USDNet income, FY2023: 612.34M USDNet income, FY2024: 791.47M USDNet income, FY2025: 229.34M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.48B USD. Revenue FY2022 7.74B USD. Revenue FY2023 8.12B USD. Revenue FY2024 8.28B USD. Revenue FY2025 8.25B USD. Operating income FY2021 378.53M USD. Operating income FY2022 795.24M USD. Operating income FY2023 956.15M USD. Operating income FY2024 1.1B USD. Operating income FY2025 1.01B USD. Net income FY2021 153.19M USD. Net income FY2022 505.3M USD. Net income FY2023 612.34M USD. Net income FY2024 791.47M USD. Net income FY2025 229.34M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue8.25B USD8.28B USD8.12B USD7.74B USD5.48B USD
Cost of goods sold6.08B USD5.85B USD5.72B USD5.53B USD3.97B USD
Gross profit2.18B USD2.44B USD2.4B USD2.21B USD1.51B USD
Selling, general, and administrative780.14M USD728.35M USD776.36M USD778.75M USD585.33M USD
Operating expenses1.16B USD1.34B USD1.44B USD1.42B USD1.13B USD
Interest income7.11M USD8.61M USD5.01M USD2.35M USD574K USD
Interest expense188.11M USD237.24M USD336.7M USD229.73M USD182.42M USD
Depreciation and amortization383M USD488.5M USD585.95M USD614.73M USD360.33M USD
Operating income1.01B USD1.1B USD956.15M USD795.24M USD378.53M USD
Net income229.34M USD791.47M USD612.34M USD505.3M USD153.19M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$170.64

0.92% downside
Past 12 months12-month forecastHigh $207Average $170.64Low $105

Recent analyst actions

12 institutions

ICLR peers

ETFs holding ICLR

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research ICLR

research.disclaimer